Pharmaceutical

Avalyn raises $175m in funding to develop inhaled IPF drugs

The funding was part of an oversubscribed Series C financing that will be used to advance its lead IPF therapies into Phase II trials.

Sep 27, 2023 - 20:00
Avalyn raises $175m in funding to develop inhaled IPF drugs
The funding was part of an oversubscribed Series C financing that will be used to advance its lead IPF therapies into Phase II trials.
Read the original article

Tags:

Previous Article

Glenmark to market Winlevi in Europe and South Africa after Cosmo deal

Next Article

Galecto downsizes by 70% following Phase II trial failure

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Investment opportunities in atopic dermatitis may drive innovation

Investment opportunities in atopic dermatitis may drive...

Sep 8, 2024

Esketamine tops quetiapine for treatment-resistant depression in head-to-head trial

Esketamine tops quetiapine for treatment-resistant depr...

Oct 4, 2023

STAT+: Heated lawsuit between AdventHealth, MultiPlan attracts hospital lobbyists

STAT+: Heated lawsuit between AdventHealth, MultiPlan a...

Jan 10, 2024